The abstract is read at the publisher; the summary is JClub's.
In uveal melanoma cells, Gq-coupled GPCRs (including HTR2B) enhance oncogenic signaling of Gαq Q209L, and HTR2B antagonists shift endogenous Gαq QL/QP toward inactivity.
- Why it matters: Most uveal melanoma patients carry Gαq Q209L or Q209P, yet how these constitutively active G proteins interact with GPCRs is unclear, limiting targeted strategies.
- What they did: The study tested Gq-coupled GPCRs such as HTR2B for effects on Gαq-Q209L signaling, then combined HTR2B antagonists with the Gαq inhibitor YM-254890 using signaling, viability, and proliferation assays.
- The result: HTR2B antagonists alone had little to no inhibitory effect, but they increased UM cell sensitivity to YM-254890 and, with low YM-254890, shifted endogenous Gαq QL/QP into an inactive conformation more than YM-254890 alone.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.